3D printed next generation diagnostic system hardware aligned with Pillar 5 of the UK diagnostic testing strategy

3D 打印的下一代诊断系统硬件符合英国诊断测试策略的第 5 支柱

• 批准号: 62915
• 金额: $ 9.56万
• 依托单位: BIOLOGIC TECHNOLOGIES LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=62915
• 关键词: 3D; printed; next; generation; diagnostic

BiologIC Technologies (Cambridge UK) is developing the next-generation of life science automation fabricated from, and exploiting, the digital benefits of 3D-printing. BiologIC's pioneering and highly integrated digital hardware architectures allow the creation of powerful and affordable 3D-printed bio-processing units ("BPUs"). These BPUs allow rapid development and execution of novel, high-value and high-volume biological workflows.The project will result in a highly innovative solution for diagnostic testing in line with the government's testing strategy, which will become a critical component of managing COVID-19 and other pandemic responses.EXTENSION FOR IMPACTUnder the extension for impact grant, BiologIC will:1. Accelerate its commercial speed-to-market2. Progress environmental and responsible innovation to reduce plastic waste and improve environmental footprint in line with PAS4403. Develop further technical capability, data, regulatory insight and scale-up plans4. Further develop its business model including its proprietary digital toolchainThe key positive impacts for society, the economy and the environment will include establishing high-throughput diagnostic testing capability that can be rapidly scaled-out on demand, significantly enhancing disease response capability and at a reduced environmental footprint versus classical approaches.

BiologIC Technologies（英国剑桥）正在开发下一代生命科学自动化，并利用3D打印的数字优势。BiologIC的开创性和高度集成的数字硬件架构允许创建功能强大且价格合理的3D打印生物处理单元（“BPU”）。这些BPU可以快速开发和执行新型、高价值和高容量的生物工作流程。该项目将为诊断测试提供高度创新的解决方案，符合政府的测试策略，这将成为管理COVID-19和其他流行病应对措施的关键组成部分。加快其商业化上市速度2.推进环保和负责任的创新，以减少塑料废物，并根据PAS 4403改善环境足迹。进一步开发技术能力、数据、监管洞察力和扩大规模计划4。对社会、经济和环境的主要积极影响将包括建立高通量诊断测试能力，可按需迅速扩大规模，显著提高疾病应对能力，并与传统方法相比减少环境足迹。